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OBJECTIVE: To determine the therapeutic effects of two selective GABA-A agonists, zopiclone and eszopiclone,
in the treatment of insomnia.
METHODS: This study comprised a phase III, single-center, randomized, double-blind, double-dummy, parallel-
group, non-inferiority trial. Patients were randomized to receive zopiclone 7.5 mg or eszopiclone 3 mg, both
orally, for four weeks. In total, 199 patients were evaluated during two visits and then followed for at least six
weeks. The primary endpoint was the Insomnia Severity Index after four weeks of treatment. Secondary
endpoints were obtained through polysomnography data, including total sleep time, sleep latency and sleep
efficiency. The frequency of adverse events was also analyzed. ClinicalTrials.gov: NCT01100164.
RESULTS: The primary efficacy analysis demonstrated the non-inferiority of eszopiclone over zopiclone. Analysis
of objective parameters assessed by polysomnography showed that eszopiclone increased total sleep time and
also improved sleep efficiency. The safety profile of both study treatments was similar and the most common
events reported in both groups were dysgeusia, headache, dizziness, irritability and nausea. Adverse events
were observed in 223 patients, 109 (85.2%) in the eszopiclone group and 114 (87.7%) in the zopiclone group.
CONCLUSION: Based on the Insomnia Severity Index at the end of four weeks of treatment, eszopiclone
demonstrated efficacy comparable to that of zopiclone in the treatment of insomnia, increasing total sleep time
as well as sleep efficiency according to polysomnography.
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Chronic insomnia affects 15% of the population (1). Although
the health consequences can be severe, few patients with this
disorder are diagnosed and treated appropriately. In addition
to negative impacts on a wide range of daytime functions,
affecting social, emotional and physical domains, chronic
insomnia affects cognitive and physical functioning (2).
Indeed, compared with people who do not suffer from
insomnia, those who present this affliction are more prone
to accidents and have higher rates of work absenteeism,
decreased work performance, decreased quality of life and
increased use of health care resources (3,4). Successful
treatment of insomnia depends on a correct diagnosis,
appropriate behavioral measures, and particularly, the use
of safe and effective drugs.
Several risk factors associated with higher chronic insom-
nia prevalence include advanced age, female sex and the
presence of comorbidities and psychiatric disorders. In
fact, approximately 40% of adults with insomnia also have
a diagnosable psychiatric disorder, especially depression and
anxiety (3,5-7).
The diagnosis is essentially clinical and based primarily on
a detailed medical history, with some additional tools for
corroboration, such as sleep diaries, actigraphy and poly-
somnography. The impact of insomnia on the quality of life of
affected individuals has been widely studied. Drugs used to
treat insomnia include hypnotics or sleep inducers as well as
antidepressants with a sedative effect (8). Among hypnotics,
sleep inducers with selective action on GABA-A receptors,
such as zolpidem, zopiclone, eszopiclone and zaleplon are
common (9,10).
Eszopiclone, a stereoisomer of zopiclone, is a non-benzodiaze-
pine hypnotic agent of the cyclopyrrolone family. Similar to
zopiclone, eszopiclone is a synthetic compound shown to be
effective in treating insomnia (11-13). The selectivity of cyclopyr-
rolones provides greater benefits compared to benzodiazepines,
as the former sustains the hypnotic effect without producing
significant anxiolytic and/or muscle relaxation effects (10).DOI: 10.6061/clinics/2016(01)02
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The efficacy of eszopiclone has been proven in patients with
insomnia associated with other comorbidities, such as a high
degree of depression, generalized anxiety, rheumatoid arthritis,
and sleep apnea, for which changes in sleep parameters are often
observed (11,12). To date, there are no studies directly comparing
the efficacy of eszopiclone and zopiclone. However, in a
study of a method for assessing dissipation of the residual
hypnotic effects of both drugs, a post hoc parametric analysis
of reciprocal-transformed data favored eszopiclone over
racemic zopiclone (14). Approved by the Food and Drug
Administration (FDA, the North-American regulatory agency)
in 2004, indications for eszopiclone in the treatment of
insomnia are not limited to its short-term use, as its efficacy
and safety have also been demonstrated in dosing studies of
six to twelve month duration.
This study, a Phase III, double-blind, single-center, non-
inferiority trial sponsored by Eurofarma Laboratórios S.A.,
aimed to determine the non-inferiority of eszopiclone (3 mg,
Eurofarma) with respect to zopiclone (7,5 mg, Imovanes, Sanofi-
Aventis) in the treatment of chronic insomnia.
’ METHODS
Patients with symptomatic insomnia for at least three
months were recruited in different ways, largely via media
and a patient database. Patients between 20 and 64 years old
with complaints of insomnia were selected at a screening
visit (SV). Diagnosis of insomnia was established according
to the criteria of the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) (15). An excep-
tion was with regard to the onset of symptoms because an
onset of over three months was considered; thus, patients
with chronic insomnia were included. Furthermore, initial
polysomnography (PSG) performed no more than 90 days
before the SV showing a total time of sleep of less than 6:30 h
was also considered a selection criterion. In addition to the
SV, the study included a baseline visit (BV; 14±3 days after
the SV), an evaluation visit (V1; 14±3 days after BV) and a
final visit (FV; 14±3 days after V1).
Exclusion criteria were as follows: the presence of other
sleep disorders, such as sleep-wake rhythm disorders and
obstructive sleep apnea with a respiratory disorder index
greater than 10/hour and the presence of periodic move-
ments of lower limbs over 15/hour; patients who were taking
psychotropics and antihistamines for at least three days prior
to study enrollment, hypnotics for less than 15 days, or herbal
medicines or melatonin for less than 14 days; the use of
hepatically metabolized drugs; a history of drug or alcohol
(ethanol) use equivalent to 35 g of alcohol/day; the presence of
severe comorbidities or psychiatric conditions; and patients
who were pregnant or lactating or who planned to become
pregnant.
A second polysomnography was performed at the end of the
study, just before FV using an EMBLA polygraph. The analysis
included electroencephalogram, electrooculogram, electromyo-
gram of muscles in the chin region and the anterior tibialis,
respiratory sensors (pressure cannula and thermistor), thoracic
and abdominal belts, snoring and position sensors and oxi-
metry. Events were classified according to the guidelines of the
American Academy of Sleep Medicine (AASM) (16).
The main assessment tool was the Insomnia Severity Index
(ISI)(17), a questionnaire consisting of five questions and
some sub-items, with replies graded from zero (best case) to
four (worst case). ISI is calculated by adding the scores for
each question, ranging from 0 to 28.
ISI was completed at BV, followed by randomization. All
volunteers were randomized in a 1:1 ratio to receive zopiclone
7.5 mg or eszopiclone 3 mg, both orally, at bedtime.
The patients were evaluated at another two visits to the
research site (visit 1 and FV) for medical history, physical
examination and sleep diary evaluation; the use of con-
comitant drugs and frequency of adverse events were also
assessed during these visits. A second polysomnography
was performed immediately before FV, after visit 1. The
follow-up period for each patient lasted at least six weeks.
Primary analysis of efficacy was achieved by evaluating
the non-inferiority of eszopiclone in relation to zopiclone
according to the ISI at the end of treatment. Secondary
variables were sleep-related parameters obtained from
nocturnal polysomnography and sleep-related data collected
during clinical visits through the Pittsburgh Sleep Quality
Index (PSQI) questionnaire (18).
The study protocol was approved by the Ethics Committee
of UNIFESP/EPM and was conducted according to local
regulations and good clinical practice. All patients partici-
pating in the study signed an informed consent form (ICF).
This study was registered at ClinicalTrials.gov with the
number NCT01100164.
Statistical methods
The statistical software R (version 2.13.1) and MedCalc
(version 11.3.3.0) were used for the statistical analysis.
Continuous variables were summarized via variation (mini-
mum and maximum values) as well as the mean, standard
deviation (SD), median and interquartile range (IIQ: 25th
percentile and 75th percentile). Categorical variables are
described by relative frequencies.
Parametric or non-parametric methods were used for
comparisons between groups according to the distribu
tion pattern of quantitative variables in the sample. The
Kolmogorov-Smirnov test with Lilliefors correction was used
to assess the pattern of distribution of the endpoint variables
in the sample. Lilliefors correction was also used to adjust the
estimated population parameters (the mean and variance or
standard deviation).
Continuous variables with a normal distribution were
compared using t-tests, whereas variables with a non-normal
distribution were compared using the non-parametric Mann-
Whitney test. Categorical variables were compared using the
chi-square test of equal proportions. ANOVA test with repeated
measures was also used for comparisons between groups over
time. As a general rule, two-sided 5% levels of significance were
used as indicators of significant differences between the groups.
FV values were used to calculate the ISI at the end of
treatment. The Kolmogorov-Smirnov test (with Lilliefors
correction) showed that the variable of interest was not
normally distributed in the analyzed sample. Thus, the non-
parametric Mann-Whitney test was used to compare the
median ISI at FV in the two treatment groups. The mean total
sleep time (TST) for the polysomnography performed bet-
ween visit 1 and FV was also compared in the per-protocol
(PP) population by the t-test.
Sample size calculation in the proposed non-inferiority
design was carried out by assuming that the ISI score after
4 weeks of treatment would be at least equal in both groups.
This was based on the literature, considering an average ISI
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score of 9.2 points with a standard deviation of 5.7 points
after four weeks of treatment for the control group. By
considering an alpha-tailed error of 5% and a statistical
power of 80% for the study to find the maximum difference
of less than 20% between the groups (non-inferiority limit),
it was estimated that 120 patients should be included in
each study arm. Assuming follow-up loss of approximately
10% of patients, the study should include 130 patients in
each arm, for a total of 260 patients.
’ RESULTS
In total, 262 volunteers assessed at the BV and 199 were
found to be eligible for enrollment: 102 in the zopiclone
group and 97 in the eszopiclone group. The demographic
characteristics of the patients are shown in Table 1. There
were no significant differences between groups.
Of the 262 randomized patients (131 in each group),
1 patient from the eszopiclone group was excluded due to
eligibility concerns, and 3 patients from the eszopiclone group
and 4 from the zopiclone group were excluded due to a lack of
endpoint data. Additionally, one from each group was
excluded because the patient did not receive the respective
drug. The ITT (intention to treat) population was composed of
126 patients in each group and the PP population included
102 and 97 patients in the zopiclone and eszopiclone groups,
respectively. There were 56 premature discontinuations during
the study; the causes are described in Table 2.
Efficacy assessment
Insomnia Severity Index. The primary analysis of efficacy
was performed by evaluating the non-inferiority of eszopiclone
with respect to zopiclone based on the ISI at the end of treatment.
The mean ISI reported at SV, BV, visit 1 and FV were 18.07±
3.84, 16.08±4.35, 6.25±5.14 and 7.41±4.95, respectively, for
patients treated with eszopiclone.
The mean ISI reported at SV, BV, visit 1 and FV were
17.86±4.08, 15.22±5.03, 7.07±4.91, 7.84±5.35, respectively,
for patients treated with zopiclone. When the groups were
compared regarding ISI values at FV, no statistically significant
difference was observed between the treatments (p=0.588).
The primary analysis of efficacy in the PP population
(eszopiclone versus zopiclone, n=199) demonstrated an
upper limit of the 90% confidence interval (0.786) below
the non-inferiority margin (M=1.567) developed during
the sample size calculations.
Pittsburgh Sleep Quality Index (PSQI)
Overall PSQI scores at FV were compared between the
two treatment groups in the PP population. No difference
between the groups regarding overall PSQI score was observed
(p=0.2486).
Polysomnography
At the end of the study, a significant difference between the
zopiclone and eszopiclone groups regarding total sleep time
was found (p=0.039), with a longer duration observed in the
latter (Table 3). A difference between the groups (p=0.018)
was also observed for sleep efficiency (SE), indicating greater
values in the eszopiclone group (mean sleep efficiency of 90%
for eszopiclone versus 86% for zopiclone) (Table 3). However,
there was no difference between the two groups regarding
sleep latency (SL, p=0.151) and time awake (TA, p=0.097)
(Table 3).
Adverse events
Adverse events were observed in 223 patients, 109 (85.2%)
in the eszopiclone group and 114 (87.7%) in the zopiclone
(p=0.552). The most frequent adverse events were dysgeusia
(eszopiclone: 65 [50.78%]; zopiclone: 78 [60%]), headache
(eszopiclone: 39 [30.47%]; zopiclone: 45 [34.62%]), dizziness (eszo-
piclone: 21 [16.41%]; zopiclone: 12 [9.23%]), irritability (eszopi-
clone: 9 [7.03%]; zopiclone: 12 [9.23%]), and nausea (eszopiclone:
9 [7.03%]; zopiclone: 8 [6.15%]). Nonetheless, there was no
statistically significant difference between the groups in the
frequency of these adverse events.
’ DISCUSSION
Zopiclone is a cyclopyrrolone that differs from zolpidem by
acting on the a1 and a2 subunits of GABA-A receptors and
presenting a half-life of 5.3 hours. The drug has demonstrated
efficacy in the treatment of early chronic insomnia or sleep
maintenance and is well tolerated by the elderly; the recom-
mended dose is 3.75 mg to 7.5 mg (8). Eszopiclone may be
used for sleep maintenance insomnia (19). This cyclo-
pyrrolone is also the first selective agonist tested in a long-
term setting (six to twelve months), with reported benefits of
improving quality of life, reducing workplace absenteeism and
decreasing the severity of insomnia (11-13). In such cases, the
recommended dose is 1 mg to 3 mg at bedtime.
This study is the first phase 3 clinical trial comparing
eszopiclone to zopiclone. The primary analysis of efficacy
performed considering the primary endpoint in the PP
population demonstrated the non-inferiority of eszopiclone
Table 1 - Demographic and clinical characteristics of the patients
in the study population (n=199).
Study population
Characteristic Eszopiclone (n=102) Zopiclone (n=97)
Age, years (mean ± SD)
[range]
48.2±10.6 [25-64] 46.5±12.1 [20-64]
Female Sex, n (%) 76 (74.5) 73 (75.3)
Race, n (%)
White 79 (77.5) 72 (74.2)
Black 8 (7.8) 14 (14.2)
Oriental 2 (2.0) 4 (4.1)
Brown 13 (12.7) 7 (7.2)
BMI, kg/m2 (mean ± SD)
[range]
27.6±4.7 [18.2-40.2] 27.0±4.6 [16.1-39.0]
Drug allergy history, n (%) 14 (13.7) 12 (12.4)
SD: standard deviation; BMI: body mass index.





Comorbidity 1 (4.0) -
Non-adherence to the protocol or
treatment
5 (20.0) 4 (12.9)
Follow-up loss 1 (4.0) 2 (6.4)
Refusal to continue treatment 3 (12.0) 4 (12.9)
Withdrawal of consent 2 (8.0) 2 (6.4)
Intolerance to study medication 9 (36.0) 15 (48.4)
Other sleep-affecting drug use 4 (16.0) 4 (12.9)
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with respect to zopiclone. This is because the upper limit of
the 90% confidence interval (CI) for the difference between
ISI means at FV for both groups (0.785) was less than the
previously established non-inferiority margin (20% of the ISI
mean in the zopiclone group, i.e., 1.567). In an exploratory
analysis, the 95% CI for the difference between the means
was also calculated, confirming the non-inferiority of
eszopiclone compared to zopiclone.
Secondary analysis of efficacy revealed significant differences
in total sleep time (p=0.039) and sleep efficiency (p=0.018), as
measured by polysomnography performed before and at the
end of treatment; such results indicate the greater efficacy of
eszopiclone in relation to these secondary variables. At the time
of polysomnography, all patients were being treated with
zopiclone or eszopiclone for at least 14 days, and the tests were
conducted as close as possible to FV. However, intra- and/or
intergroup differences may eventually have occurred due to a
possible different timing of polysomnography. Because the
present study focused on the clinical response of insomnia
severity to eszopiclone and zopiclone, blood and urine tests or
other markers were not analyzed.
The safety profile of both study treatments was similar. No
statistically significant differences between the treatments
were found for adverse events that were recorded in both
groups and could be compared with regard to frequency. The
most common events reported for both study treatments
were dysgeusia, headache, dizziness, irritability, and nausea.
The adverse effects of zopiclone are similar to zolpidem,
including headache, dizziness and somnolence (19). None-
theless, dysgeusia appears to be the most commonly found
adverse event for both zopiclone and eszopiclone.
This study has some limitations. Although 96.2% of the
patients were included in the ITT analysis, only 76% were
included in the PP analysis. Patients with severe comorbid-
ities or those using other sleep-inducing drugs, which is very
common in cases of insomnia, were not included. In
addition, the duration of insomnia was not quantified (even
though every patient was diagnosed with chronic insomnia),
and the period evaluated comprised only 4 weeks. Finally,
because they were related in 2-week intervals, adverse events
may have been underestimated.
Eszopiclone is effective in the treatment of insomnia,
improving the severity of insomnia and demonstrating a
favorable safety profile. Treatment with eszopiclone also
resulted in longer total sleep time and greater sleep efficiency
by polysomnography than zopiclone. However, further studies
may be required to validate the polysomnographic results.
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